HIP
VRTX icon

Hatteras Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Hatteras Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-16,597
Closed -$1.96M – 135
2015
Q1 		$1.96M Buy
+16,597
New +$1.99M 1.05% 30

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Hatteras Investment Partners's VRTX Position: Q2 2015 in Review

Hatteras Investment Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2015, closing a stake of 16,597 shares — an estimated $1.96M sold.

Hatteras Investment Partners first reported a position in VRTX in Q1 2015 and held it in 1 quarter. The position peaked at $1.96M in Q1 2015. 500 funds tracked by Wall St. Rank hold VRTX as of Q2 2015.

  • Hatteras Investment Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Hatteras Investment Partners sold 16,597 Vertex Pharmaceuticals shares in Q2 2015, an estimated $1.96M.
  • Hatteras Investment Partners first reported a position in Vertex Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Hatteras Investment Partners's Vertex Pharmaceuticals position peaked at $1.96M in Q1 2015.
  • 500 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2015.

Based on Hatteras Investment Partners's 13F filing for Q2 2015, filed 13 Aug 2015.